Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.
about
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.Retracted: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans.Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Explaining Ethnic Variability of Transporter Substrate Pharmacokinetics in Healthy Asian and Caucasian Subjects with Allele Frequencies of OATP1B1 and BCRP: A Mechanistic Modeling Analysis.Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations.Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach.Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling.Precision medicine: does ethnicity information complement genotype-based prescribing decisions?Comparison of exposure response relationship of atrasentan between North American and Asian populations.Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information.Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans.
P2860
Q33443406-2524298A-619C-453D-AD6C-BA93B2B94C61Q33581531-7F5DB4F4-003C-4AFB-AFAB-6BE1FB0A556DQ36233941-C9CFC08F-704E-46E1-A85E-A9AF6DEC58FDQ37279044-B734A75C-0BAB-42CF-A4CA-AB907F5C9043Q37394474-564F9754-47E1-4FA1-A275-285429672E6BQ38233298-72AAC88B-DC3B-4582-9260-BCBA34A82B64Q38707798-654B8AFE-56AE-4C71-AB99-3A5CCB37837EQ38719689-60887F4A-3791-436E-8A36-D5ABDC9C214EQ38855314-E6AF3F74-1C2A-45B7-BE43-82D4A3F7B34FQ39034284-AF1225A8-1120-49BB-9C10-751F8BD4BF98Q40431727-D5DA3D60-454F-4721-9741-DE890938830BQ40829783-D4DCF835-1136-45B1-8059-FDD90EA9452EQ41706349-08231F3A-7379-4E06-AC20-290C0C5771FCQ41759104-532739A8-FE17-410C-BE38-5178FB1C1767Q43965937-8A8C61A2-1D83-4AEC-88B5-B1CDD6A2C151Q44737065-F7E096A4-5C07-4A24-BEE8-6C0B170A157FQ46204648-CED291A4-16F6-4F4C-AC76-2677EC01D760Q46942949-53A94FE6-4F90-41E6-80F2-EB52E1D5A62BQ47566249-8CF39B78-962E-42EE-BACA-BC2793FEEF8AQ48650147-3F9E426C-7585-493A-A1B7-3F6E1269463EQ53611791-EBCDAB06-A1EF-488E-B40B-8502A6D6CCFFQ54053216-40EC4C86-B9C7-4024-8A94-305643BC547CQ55386205-2CD52AA3-79C4-4874-9B2D-34702056C66BQ55518566-1C18F7C4-CE29-45E8-96E5-00748B164BC1
P2860
Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Ethnic variability in the plas ...... onsideration of its mechanism.
@en
type
label
Ethnic variability in the plas ...... onsideration of its mechanism.
@en
prefLabel
Ethnic variability in the plas ...... onsideration of its mechanism.
@en
P2093
P2860
P356
P1476
Ethnic variability in the plas ...... onsideration of its mechanism.
@en
P2093
P2860
P2888
P356
10.1038/CLPT.2012.221
P407
P577
2012-11-07T00:00:00Z
P5875
P6179
1042318167